Abstract
In this Practice Point commentary, I discuss the findings and clinical implications of the bone substudy of the phase III, open-label, randomized Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12). Gnant et al. assessed changes in BMD in 404 premenopausal women with early-stage breast cancer who received different adjuvant endocrine therapies, with or without concomitant bone-protective therapy (4 mg intravenous zoledronic acid twice-yearly). The authors demonstrated rapid bone loss after ovarian suppression with goserelin plus either a selective estrogen-receptor modulator (tamoxifen) or an aromatase inhibitor (anastrozole). Bone loss was particularly marked in patients who received a combination of goserelin and anastrozole; losses were only partially reversed on treatment withdrawal. Zoledronic acid prevented bone loss associated with both endocrine therapies. The study of Gnant et al. provides useful descriptive data, but is limited by its lack of data on fracture incidence. Furthermore, the authors were unable to define the specific population of patients who require intervention with a bisphosphonate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Winer EP et al. (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619–629
Eastell R et al. (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26: 1051–1057
Coleman RE et al. (2008) Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 34 (Suppl 1): S31–S42
Gnant M et al. (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9: 840–849
Black DM et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822
Reid DM et al. (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34 (Suppl 1): S3–S18
Hadji P et al. (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19: 1407–1416
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Robert E Coleman has declared the following associations: Amgen (consultant and speakers bureau) and Novartis (consultant, speakers bureau and grant/research support).
Rights and permissions
About this article
Cite this article
Coleman, R. Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer. Nat Rev Endocrinol 5, 72–73 (2009). https://doi.org/10.1038/ncpendmet1045
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet1045